CVnCoV – CureVac AG vs placebo
Any adverse eventj
CVnCoV – CureVac AG probably leads to higher any adverse eventj compared with placebo (moderate certainty).
1 finding from 1 review
- RR 1.42 [1.38, 1.47]1 study · 3982 participantsModerate
CVnCoV – CureVac AG probably leads to higher any adverse eventj compared with placebo (moderate certainty).